Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00835120 · ClinicalTrials.gov registry record · Phase 4
Pioglitazone for the Treatment of Bipolar Disorder and Comorbid Metabolic Syndrome or Insulin Resistance
A Phase 4 study, sponsored by University Hospitals Cleveland Medical Center.
- Completed
- Registry status
- Phase 4
- Development phase
- 34
- Enrollment target
NCT00835120 is a Phase 4 study that has completed, run by University Hospitals Cleveland Medical Center. The registered enrollment target is 34 participants.
The verdict
NCT00835120, a Phase 4 study, has completed, sponsored by University Hospitals Cleveland Medical Center.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 34 participants
- Enrollment target
Study Summary
The study is an open-label 8-week adjunctive trial of pioglitazone for the acute relief of bipolar depression comorbid with metabolic syndrome/insulin resistance. Subjects who experience a partial or full response will have the option of continuing in an acute continuation phase lasting up to 12 weeks. The extension phase will allow assessment of the safety and tolerability of pioglitazone during the acute continuation period.
Interventions
- DRUG Pioglitazone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2009-03 |
| Est. Completion | 2013-04 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00835120
The ClinicalTrials.gov registry entry for NCT00835120 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University Hospitals Cleveland Medical Center, which has 230 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Pioglitazone is the first listed.
NCT00835120 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00835120 about?
NCT00835120 is a clinical study titled "Pioglitazone for the Treatment of Bipolar Disorder and Comorbid Metabolic Syndrome or Insulin Resistance". The study is an open-label 8-week adjunctive trial of pioglitazone for the acute relief of bipolar depression comorbid with metabolic syndrome/insulin resistance. Subjects who experience a partial or full response will have the option of continuing in an acute continuation phase lasting up to 12 wee...
What is the current status of trial NCT00835120?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 34 participants. The study started on 2009-03. Estimated completion is 2013-04.
What interventions are being tested in trial NCT00835120?
The interventions under investigation include: Pioglitazone (DRUG).
Who is sponsoring clinical trial NCT00835120?
This trial is sponsored by University Hospitals Cleveland Medical Center, which has 230 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.